Skip to main content
SpringerLink
Log in

Intranasal Metoclopramide

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Intranasal metoclopramide is a new formulation of an established and effective antiemetic drug.

  • ▴ Absorption after intranasal administration was lower than after oral or intravenous administration; otherwise the pharmacodynamic and pharmacokinetic profiles of the intranasal and parenteral formulations were similar.

  • ▴ Intranasal and intramuscular metoclopramide showed similar efficacy in the control of acute emesis induced by moderately emetogenic chemotherapy in 12 patients. Intranasal metoclopramide 80mg significantly reduced the frequency of acute vomiting in 43 patients receiving highly emetogenic chemotherapy.

  • ▴ A pilot study suggested that intranasal metoclopramide, with or without dexamethasone, may reduce cisplatin-induced delayed emesis. In a randomised crossover trial in 40 patients, intranasal metoclopramide or oral metoclopramide, both with dexamethasone, were equally effective in the control of delayed emesis induced by moderately-emetogenic chemotherapy.

  • ▴ One 30 patient study suggests that intranasal metoclopramide has similar efficacy to oral metoclopramide in the treatment of functional dyspepsia.

  • ▴ A non-significant trend to reducing postoperative nausea and vomiting has been seen in two trials of intra-nasal metoclopramide.

  • ▴ Intranasal metoclopramide caused minor irritation of the nasal membrane and unpleasant taste in some patients, but was otherwise well tolerated. None of the more serious extrapyramidal effects sometimes associated with metoclopramide were reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15(1): 124–30

    Google Scholar 

  2. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health System Pharm 1999; 56: 729–64

    Google Scholar 

  3. Roila F, Ballatori E. The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol 1998 Jul; 10: 310–5

    Article  PubMed  CAS  Google Scholar 

  4. Grunberg SM. Cost-effective use of antiemetics. Oncology Huntingt 1998 Mar; 12(3) Suppl. 4: 38–42

    PubMed  CAS  Google Scholar 

  5. Citron ML, Reynolds JR, Kalra J, et al. Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers. Cancer Treat Rep 1987; 71(3): 317–9

    PubMed  CAS  Google Scholar 

  6. Ward MJ, Buss DC, Ellershaw J, et al. Bioavailability of intranasal metoclopramide. Br J Clin Pharmacol 1989 Nov; 28: 616–8

    Article  PubMed  CAS  Google Scholar 

  7. Scaglione F, Scanni A, Tomirotti M, et al. Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. Arzneimittel Forschung 1993 Sep; 43(11): 986–8

    PubMed  CAS  Google Scholar 

  8. Harrington RA, Hamilton CW, Brogden JA, et al. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983; 25(5): 451–94

    CAS  Google Scholar 

  9. Mitchelson F. Pharmacologic agents affecting emesis: a review (part I). Drugs 1992; 43(3): 295–315

    Article  PubMed  CAS  Google Scholar 

  10. Fozard JR, Mobarok Ali AT. Blockade of neuronal tryptamine receptors by metoclopramide. EurJPharmacol 1978; 49: 109–12

    Article  CAS  Google Scholar 

  11. Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol 1995 Aug; 22 Suppl. 10: 6–18

    PubMed  CAS  Google Scholar 

  12. Gralla RJ. A double-blind multiple dose study of the efficacy and safety of 20mg, 40mg and 80mg of intranasal metoclopramide compared to placebo in cancer patients treated with emetogenic chemotherapeutic agents. Crinos Industria Farmacobiologica S.p.A., Como, Italy, 1993, Report no. U-90-01. (Data on file)

  13. Weber W, Pabst G, Dilger C, et al. Pharmacokinetics/Bioavailability evaluation of four metoclopramide preparations in 28 health volunteers. Naska Pharmacal Inc./RiboGene Inc.,Hayward CA, USA, 1991, Protocol no. 90762. (Data on file)

  14. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3(10): 1379–84

    PubMed  CAS  Google Scholar 

  15. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996 Nov; 52(5): 639–48

    Article  PubMed  CAS  Google Scholar 

  16. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40

    CAS  Google Scholar 

  17. Tomirotti M, Dimaiuta M, Confalonieri M, et al. Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients: a controlled clinical study. Support Care Cancer 1994 Nov; 2: 389–92

    Article  PubMed  CAS  Google Scholar 

  18. Eckhardt S, Ady N, Baki M, et al. A double-blind multiple dose parallel arm comparison of the antiemetic and antinausea efficacy and safety of 20mg and 40mg intranasal metoclopramide compared to placebo in cancer patients treated with emetogenic chemotherapeutic agents, a phase III clinical trial. Crinos Industria Farmacobiologica S.p.A., Como, Italy, 1991. Report no. U-90-02/A. (Data on file)

  19. Bodrogi I, Baki M, Horti J, et al. A double-blind multiple dose parallel arm study of the antiemetic and antinausea efficay and safety of 20mg and 40mg intranasal metoclopramide compared to placebo in cancer patients treated with emetogenic chemotherapeutic agents. Crinos Industria Farmacobilogica S.p.A., Como, Italy, 1992. Report no. U-91-02BH. (Data on file)

  20. Chiara S, Campora E, Rosso R. Controllo dell’emesi tardiva: studio randomizzato di confronta metoclopramide spray nasale + desametasone versus metoclopramide compresse + desametasone in pazienti riceventi chemioterapia a moderato potere emetizzante. Crinos Industria Farmacobiologica S.p.A., Como Italy, 1994. Protocol no. MCP 02/92. (Data on file)

  21. Chiara S, Campora E, Simoni C, et al. Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment. Anti-cancer Res 1995; 15: 1597–600

    CAS  Google Scholar 

  22. Locatelli MC, Pessi A, D’Antona A, et al. Tolerability and safety of nasally administered metoclopramide for the prevention of cis-platinum (CDDP)induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 533

    Google Scholar 

  23. Locatelli C, D’Antona A. Metoclopramide nasal spray in the prevention of delayed hyperemsis in neoplastic patients under cisplatin chemotherapy: uncontrolled pilot study. Crinos Industria Farmacobiologica S.p.A, Como, Italy, 1997. Protocol no. MCP 01/92. (Data on file)

  24. Lin DM, Furst SR, Rodarte A. A double-blind comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery. Anesthesiology 1992; 76: 357–61

    Article  PubMed  CAS  Google Scholar 

  25. Wagner BKJ, Berman SL, Devitt PA, et al. A double-blind, placebo-controlled evaluation of intranasal metoclopramide in the prevention of postoperative nausea and vomiting. Pharmacotherapy 1996 Nov–Dec; 16(6): 1063–9

    PubMed  CAS  Google Scholar 

  26. Battito M, Khairallah P, Conroy J, et al. A double-blind, dose-finding study to assess the safety and efficacy of intranasal metoclopramide vs placebo in the treatment of postoperative nausea or vomiting. Crinos Industria Farmacobiologica S.p.A., Como, Italy, 1992. Protocol no. U-90-04A. (Data on file)

  27. Bortoli A, Prada A, Confalonieri M, et al. Efficacy and tolerability of metoclopramide nasal spray in the symptomatic therapy of functional dyspepsia. Curr Ther Res 1994; 55: 1192–200

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 10, New Zealand

    Douglas Ormrod & Karen L. Goa

Authors
  1. Douglas Ormrod
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Ormrod.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ormrod, D., Goa, K.L. Intranasal Metoclopramide. Drugs 58, 315–322 (1999). https://doi.org/10.2165/00003495-199958020-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958020-00012

Search

Navigation